{
  "drug_name": "Idarucizumab",
  "url": "https://wikem.org/wiki/Idarucizumab",
  "scraped_at": "2026-01-10T07:55:20.705679",
  "sections": {
    "Administration": {
      "text": "Type: Humanized monoclonal antibody fragment,\nantidote\n/\nanticoagulant reversal\nDosage Forms: 2.5g/50ml vial\nRoutes of Administration: IV\nCommon Trade Names: PRAXBIND",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "antidote",
          "url": "https://wikem.org/wiki/Antidote"
        },
        {
          "text": "anticoagulant reversal",
          "url": "https://wikem.org/wiki/Anticoagulant_reversal"
        }
      ]
    },
    "Adult_Dosing": {
      "text": "5g (2 vials)\nLimited evidence for redosing or dosing above 5g",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "No safety data available",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: B, no studies exist\nLactation risk\n: Not studied",
      "subsections": {
        "Renal_Dosing": {
          "text": "Adult: 5g",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Adult: Not studied",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        },
        {
          "text": "Lactation risk",
          "url": "https://wikem.org/wiki/Lactation_risk_categories"
        }
      ]
    },
    "Renal_Dosing": {
      "text": "Adult: 5g",
      "subsections": {
        "Hepatic_Dosing": {
          "text": "Adult: Not studied",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hepatic_Dosing": {
      "text": "Adult: Not studied",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "None",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "Thromboembolic Risk: Reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease. Resume anticoagulant therapy as soon as medically appropriate.\nRe-elevation of Coagulation Parameters: In patients with elevated coagulation parameters and reappearance of clinically relevant bleeding or requiring a second emergency surgery/urgent procedure, an additional 5 g dose of PRAXBIND may be considered.\nHypersensitivity reactions: Discontinue administration and evaluate.\nRisks of Serious Adverse Reactions in Patients with Hereditary Fructose Intolerance due to Sorbitol Excipient: Patients with hereditary fructose intolerance may be at risk of adverse reactions.",
          "tables": []
        },
        "Common": {
          "text": "In healthy volunteers, the most frequently reported adverse reactions in ≥5% of subjects treated with idarucizumab was headache\nIn patients, the most frequently reported adverse reactions in ≥5% of patients treated with idarucizumab were hypokalemia, delirium, constipation, pyrexia, and pneumonia",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Serious": {
      "text": "Thromboembolic Risk: Reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease. Resume anticoagulant therapy as soon as medically appropriate.\nRe-elevation of Coagulation Parameters: In patients with elevated coagulation parameters and reappearance of clinically relevant bleeding or requiring a second emergency surgery/urgent procedure, an additional 5 g dose of PRAXBIND may be considered.\nHypersensitivity reactions: Discontinue administration and evaluate.\nRisks of Serious Adverse Reactions in Patients with Hereditary Fructose Intolerance due to Sorbitol Excipient: Patients with hereditary fructose intolerance may be at risk of adverse reactions.",
      "subsections": {
        "Common": {
          "text": "In healthy volunteers, the most frequently reported adverse reactions in ≥5% of subjects treated with idarucizumab was headache\nIn patients, the most frequently reported adverse reactions in ≥5% of patients treated with idarucizumab were hypokalemia, delirium, constipation, pyrexia, and pneumonia",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Common": {
      "text": "In healthy volunteers, the most frequently reported adverse reactions in ≥5% of subjects treated with idarucizumab was headache\nIn patients, the most frequently reported adverse reactions in ≥5% of patients treated with idarucizumab were hypokalemia, delirium, constipation, pyrexia, and pneumonia",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 10.3h\nMetabolism: Protein catabolism\nExcretion: Renal",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Mechanism_of_Action": {
      "text": "Fab that binds to dabigatran and its acylglucuronide metabolites with higher affinity than the binding affinity of dabigatran to thrombin, neutralizing their anticoagulant effects",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Comments": {
      "text": "FDA approved idarucizumab after preliminary results of the Reversal Effects of Idarucizumab on Active Dabigatran (RE-VERSE AD) study.\n[1]",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "See_Also": {
      "text": "Dabigatran (Pradaxa) reversal",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Dabigatran (Pradaxa) reversal",
          "url": "https://wikem.org/wiki/Dabigatran_(Pradaxa)_reversal"
        }
      ]
    }
  }
}